Stay updated with breaking news from Opinion Based. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Takeda TSE4502NYSETAK today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval under exceptional circumstances of recombinant ADAMTS13 rADAMTS13 for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP.
Takeda TSE4502NYSETAK today announced the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval of HYQVIA Immune Globulin Infusion 10 Human with Recombinant Human Hyaluronidase in patients with chronic inflammatory demyelinating polyneuropathy CIDP as maintenance therapy after stabilization with intravenous immunoglobulin therapy IVIG.
If Approved, HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Would Offer an up to Once-Monthly Facilitated Subcutaneous…
ZURICH, Sept. 22, 2023 /PRNewswire/ -- Takeda (TSE:4502) (NYSE:TAK) today announced the European Medicines...
EbvalloTM on Track to be the First Ever Allogeneic T-Cell Therapy Approved Positive Opinion Based on Pivotal Phase 3 ALLELE Study Demonstrating a Favorable Risk-Benefit Profile European Commission